EC Number   |
Source Tissue |
Reference |
|---|
    3.1.1.2 | BEAS-2B cell |
- |
708087 |
| 3.1.1.2 | blood |
- |
703470, 728957, 749840, 750340 |
| 3.1.1.2 | blood |
of patients with disorders of galactose metabolism. Low total antioxidant status and high galactose 1-phosphate levels may reduce activity of paraoxonase 1/arylesterase |
679293 |
| 3.1.1.2 | blood |
PON1 activity is lower in chronic hepatitis patients compared with the control subjects |
671006 |
| 3.1.1.2 | blood plasma |
- |
665028, 678376, 678464, 681730, 691230, 691855, 693321, 693517, 695193, 714002, 714637 |
| 3.1.1.2 | blood serum |
- |
35213, 35215, 646527, 650953, 664184, 665960, 666183, 677892, 679182, 679306, 749610, 749628, 750345, 750428, 750482, 750483, 750511, 750758, 752150, 752173 |
| 3.1.1.2 | blood serum |
contains A-type paraoxonase and B-type paraoxonase |
646527 |
| 3.1.1.2 | blood serum |
enzyme activity against the phenylacetate is higher, and phenotype-dependent, only in diabetic patients with type II diabetes mellitus. Less antiatherogenic paraoxonase B allele is more frequent in type II diabetes mellitus than in the healthy population. Their lipid status is more atherogenic, which could indicate a risk of premature atherosclerosis |
677411 |
| 3.1.1.2 | blood serum |
in serum, the esterase is tightly bound to the high density lipoproteins, particularly apo A-l |
646509 |
| 3.1.1.2 | blood serum |
in the blood of Gulf War veterans who developed delayed neurotoxicity symptoms the levels of serum paraoxonase (PON1) isozyme type Q is significantly lower than in the control, unaffected veteran group |
646528 |
